

**GUFIC BIOSCIENCES LIMITED**

Regd. office : 2nd Floor, Building A, Moti Baug, 118/119, S.V. Road, Andheri (West), Mumbai-400 058

**AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2013**

Rs. In Lacs

Particulars	Quarter Ended 31.03.2013 Audited	Quarter Ended 31.12.2012 Unaudited	Quarter Ended 31.03.2012 Unaudited	For the Year Ended 31.03.2013 Audited	For the Year Ended 31.03.2012 Audited
<b>INCOME:</b>					
Net Sales / Income from Operations (Net of Excise Duty)	2452.22	2461.77	2172.32	9998.31	8341.16
Other Operating Income	13.68	14.77	6.20	42.45	39.92
<b>Total Income from Operations (Net)</b>	<b>2465.90</b>	<b>2476.54</b>	<b>2178.52</b>	<b>10040.76</b>	<b>8381.08</b>
<b>EXPENSES:</b>					
Cost of Materials Consumed	736.88	965.71	473.33	3583.41	2588.85
Purchase of Stock-in-Trade	474.55	355.15	575.64	1626.26	1953.39
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	93.10	(57.38)	(39.14)	(107.75)	(46.22)
Employee Benefits Expenses	175.86	130.20	128.84	544.85	460.28
Depreciation and Amortisation Expenses	64.32	50.99	38.99	217.95	188.12
Other Expenses	657.41	810.25	877.19	3278.98	2688.78
<b>Total Expenses</b>	<b>2202.11</b>	<b>2254.93</b>	<b>2054.85</b>	<b>9143.70</b>	<b>7833.20</b>
<b>Profit from Operations before Other Income, finance costs and Exceptional Items</b>	<b>263.78</b>	<b>221.61</b>	<b>123.68</b>	<b>897.05</b>	<b>547.88</b>
Other Income	17.80	3.13	32.94	21.55	12.20
<b>Profit from ordinary activities before finance costs and exceptional items</b>	<b>281.58</b>	<b>224.75</b>	<b>156.62</b>	<b>918.60</b>	<b>560.08</b>
Finance Costs	147.42	94.25	84.44	383.00	263.07
<b>Profit from ordinary activities after finance costs but before exceptional items</b>	<b>134.16</b>	<b>130.49</b>	<b>72.18</b>	<b>535.60</b>	<b>297.01</b>
Exceptional Items	0.00	0.00	0.00	0.00	0.00
<b>Profit from Ordinary Activities Before Tax</b>	<b>134.16</b>	<b>130.49</b>	<b>72.18</b>	<b>535.60</b>	<b>297.01</b>
Tax Expenses	62.79	45.40	63.01	202.69	144.30
<b>Net Profit from Ordinary Activities After Tax</b>	<b>71.37</b>	<b>85.09</b>	<b>9.16</b>	<b>332.92</b>	<b>152.71</b>
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00
<b>Net Profit for the Period</b>	<b>71.37</b>	<b>85.09</b>	<b>9.16</b>	<b>332.92</b>	<b>152.71</b>
 Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	 773.50	 773.50	 773.50	 773.50	 773.50
Reserves Excluding Revaluation Reserves	1465.89	1439.46	1222.23	1465.89	1177.92
 E.P.S	 0.09	 0.11	 0.01	 0.43	 0.20
 <b>Public Shareholding</b>					
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23322337	23222355	23322337
-- Percentage of shareholding	30.02%	30.02%	30.15%	30.02%	30.15%
 <b>Promoters and Promoter group Shareholding</b>					
a) Pledged / Encumbered					
-- Number of Shares of Rs 1 /- Each	0	0	0	0	0
-- Percentage of Shares the total Shareholding					
-- Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered					
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54027663	54127645	54027663
-- Percentage of Shares the total Shareholding					
-- of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.85%	69.98%	69.85%

The above Results for the quarter and year ended 31st March, 2013 were reviewed by the Audit Committee and thereafter were approved by the Board of Directors at their meeting held on 30th May, 2013

For GUFIC BIOSCIENCES LTD.



 Jayesh P. Choksi  
Managing Director

 Place: Mumbai  
Date: 30.05.2013



**AUDITED SEGMENT WISE RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2013**

Particulars	Quarter Ended 31.03.2013 Audited	Quarter Ended 31.12.2012 Unaudited	Quarter Ended 31.03.2012 Unaudited	For the Year Ended 31.03.2013 Audited	For the Year Ended 31.03.2012 Audited
<b>SEGMENT REVENUE</b>					
Sales & Service					
Pharma	2281.80	2239.04	2004.93	9085.06	7670.26
Consumer	170.42	222.73	167.39	913.25	670.90
<b>Total</b>	<b>2452.22</b>	<b>2461.77</b>	<b>2172.33</b>	<b>9998.31</b>	<b>8341.16</b>
Unallocated Income	31.47	17.90	39.14	84.00	52.12
<b>Total Segment Revenue</b>	<b>2483.69</b>	<b>2479.67</b>	<b>2211.47</b>	<b>10062.31</b>	<b>8393.28</b>
<b>SEGMENT RESULTS</b>					
Pharma	442.42	434.13	378.56	1761.51	1487.19
Consumer	32.97	43.08	35.03	176.68	129.78
<b>TOTAL</b>	<b>475.39</b>	<b>477.21</b>	<b>413.59</b>	<b>1938.17</b>	<b>1616.97</b>
Less: Unallocated over heads	129.50	201.47	217.98	801.62	868.78
Finance Charges	147.42	94.25	84.44	383.00	263.07
Depreciation	64.32	50.99	38.99	217.95	188.12
Tax provision	62.79	45.40	63.01	202.69	144.30
<b>Net Profit after Tax</b>	<b>71.37</b>	<b>85.09</b>	<b>9.16</b>	<b>332.92</b>	<b>152.71</b>

**AUDITED STATEMENT OF ASSETS AND LIABILITIES**

Particulars	Rs. in Lacs	
	AS AT 31.03.2013 Audited	AS AT 31.03.2012 Audited
<b>EQUITY AND LIABILITIES</b>		
a) Shareholder's Funds		
Share Capital	773.50	773.50
b) Reserves and Surplus	1485.89	1177.92
Sub-total - Shareholder's Funds	<b>2259.39</b>	<b>1951.42</b>
Non-current liabilities		
a) Long-term borrowings	1841.60	431.80
b) Deferred tax liabilities (Net)	294.69	241.50
c) Other long-term liabilities	95.50	101.50
d) Long-term provisions	118.68	89.73
Sub-total - Non-current liabilities	<b>2350.46</b>	<b>874.53</b>
Current liabilities		
a) Short-term borrowings	1373.68	1531.97
b) Trade payables	2071.77	2221.56
c) Other current liabilities	718.79	642.28
d) Short-term provisions	203.55	191.02
Sub-total - Current liabilities	<b>4367.79</b>	<b>4586.83</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>8957.64</b>	<b>7412.78</b>
<b>ASSETS</b>		
Non-current assets		
a) Fixed assets	2980.64	1877.59
b) Non-current investments	0.92	0.92
c) Long-term loans and advances	726.52	548.86
d) Other non-current assets	10.46	5.18
Sub-total - Non-Current assets	<b>3718.54</b>	<b>2432.55</b>
Current assets		
a) Current investments	0.00	0.00
b) Inventories	1989.59	1690.94
c) Trade receivables	2183.00	2257.15
d) Cash and cash equivalents	127.83	96.27
e) Short-term loans and advances	722.09	860.88
f) Other current assets	186.59	75.01
Sub-total - Non-Current assets	<b>5239.10</b>	<b>4980.23</b>
<b>TOTAL - ASSETS</b>	<b>8957.64</b>	<b>7412.78</b>

- 1> The above Results for the quarter and year ended 31st March, 2013 were reviewed by the Audit Committee and thereafter were approved by the Board of Directors at their meeting held on 30th May, 2013
- 2> Investors Complaints received and disposed off during the Quarter Ended 31st March, 2013.
- |                                                       |     |
|-------------------------------------------------------|-----|
| Complaints Pending at the Beginning of the quarter    | Nil |
| Complaints received during the quarter                | Nil |
| Disposal of Complaints                                | Nil |
| Complaints lying unresolved at the end of the quarter | Nil |
- 3> Previous periods' figures have been regrouped, rearranged, reworked or reclassified wherever necessary to confirm to the current periods' classification

For GUFIC BIOSCIENCES LTD.



Place: Mumbai  
 Date: 30.05.2013

Jayesh P. Choksi  
 Managing Director